Postoperative Use of Bevacizumab as an Antifibrotic Agent in Glaucoma Filtration Surgery in the Rabbit
The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
PURPOSE: To evaluate the efficacy of bevacizumab as an antifibrotic agent after trabeculectomy in rabbits. METHODS: Forty-two rabbits underwent trabeculectomy and were randomly assigned to receive a postoperative course of seven subconjunctival injections of bevacizumab (1.25 mg, 25 mg/mL), 5-fluorouracil (5-FU; 5 mg, 50 mg/mL), or balanced salt solution (BSS; 0.1 mL, control). Bleb survival and characteristics were evaluated over a 30-day period. The animals were killed on postoperative day (PD)10, PD20, and PD30. Histology and immunohistochemistry of the surgical eyes was performed to evaluate and grade the amount of scarring and fibrosis in each group. RESULTS: Bevacizumab significantly improved the outcome of filtration surgery in this model. Bevacizumab prolonged bleb survival compared with the 5-FU and control groups (16.0 +/- 1.3 days vs. 6.9 +/- 0.6 and 7.4 +/- 0.85 days, respectively; P < 0.001). Bevacizumab-treated eyes had significantly larger and higher blebs than the control and 5-FU-treated groups (P < 0.05). Histologic analysis revealed that eyes treated with bevacizumab had significantly less postoperative scarring at the microscopic level at PD10 and PD20 (P = 0.009). CONCLUSIONS: Postoperative subconjunctival injection of bevacizumab is associated with improved trabeculectomy bleb survival in the rabbit model. Bevacizumab may be a useful agent for improving success and limiting scar tissue formation after trabeculectomy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Bevacizumab is reported to have antifibrotic activity that reduces scar formation in glaucoma filtration surgery.29–31”
From Risk of Scar in the Comparison of Age-related Macular Degeneration Treatments Trials (2014) · cites this paper as [31]
Citations
Cites
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968 · cited 1×
“Bevacizumab is an antibody against VEGF that has been approved by the US Food and Drug Administration for the treatment of colorectal cancer.(11) Several case reports have described the successful, off-label intravitreal use of bevacizumab for treatment of neovascularization associated with proliferative diabetic reti…”
Vascular Endothelial Growth Factor and Angiogenesis
Hoeben, A., Landuyt, B., Highley, M. S., Wildiers, H., Van Oosterom, A. T., & De Bruijn, E. A. (2004) · Pharmacological Reviews · doi:10.1124/pr.56.4.3 · Cited by 1,824
Intravitreal Bevacizumab (Avastin) for Neovascular Age-Related Macular Degeneration
Avery, R. L., Pieramici, D. J., Rabena, M. D., Castellarin, A. A., Nasir, M. A., & Giust, M. J. (2006) · Ophthalmology · doi:10.1016/j.ophtha.2005.11.019 · Cited by 1,133
Angiogenesis in wound repair: Angiogenic growth factors and the extracellular matrix
Li, J., Zhang, Y., & Kirsner, R. S. (2003) · Microscopy Research and Technique · doi:10.1002/jemt.10249 · Cited by 740 · cited 1×
“Angiogenesis, which allows for early migration of inflammatory cells and fibroblasts into the wound and the release of key mitogenic cytokines such as fibroblast growth factor, is a critical component of the wound-healing process.(8,9) Vascular endothelial growth factor (VEGF) is one of the most potent cytokines in wo…”
Wound healing in glaucoma filtering surgery
Skuta, G. L., & Parrish, R. K. (1987) · Survey of Ophthalmology · doi:10.1016/0039-6257(87)90091-9 · Cited by 630 · cited 1×
“The most common reason for trabeculectomy failure is the development of fibrosis in the conjunctiva and episclera because of progressive fibroblast proliferation and collagen deposition at the site of the filtration bleb.(1,2) This frequently leads to poor postoperative intraocular pressure control with subsequent pro…”
Asahara, T., Bauters, C., Zheng, L. P., Takeshita, S., Bunting, S., Ferrara, N., Symes, J. F., & Isner, J. M. (1995) · Circulation · doi:10.1161/01.cir.92.9.365 · Cited by 596 · cited 1×
“Angiogenesis, which allows for early migration of inflammatory cells and fibroblasts into the wound and the release of key mitogenic cytokines such as fibroblast growth factor, is a critical component of the wound-healing process.(8,9) Vascular endothelial growth factor (VEGF) is one of the most potent cytokines in wo…”
Five-year Follow-up of the Fluorouracil Filtering Surgery Study
THE FLUOROURACIL FILTERING SURGERY STUDY GROUP (1996) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(14)70431-3 · Cited by 526
Migdal, C., Gregory, W., & Hitchings, R. (1994) · Ophthalmology · doi:10.1016/s0161-6420(94)31120-1 · Cited by 373
Regulation of scar formation by vascular endothelial growth factor
Wilgus, T. A., Ferreira, A. M., Oberyszyn, T. M., Bergdall, V. K., & DiPietro, L. A. (2008) · Laboratory Investigation · doi:10.1038/labinvest.2008.36 · Cited by 319
Effects of 5-fluorouracil and Mitomycin C on Cultured Rabbit Subconjunctival Fibroblasts
Yamamoto, T., Varani, J., Soong, H. K., & Lighter, P. R. (1990) · Ophthalmology · doi:10.1016/s0161-6420(90)32456-9 · Cited by 271
Cited by
Items 101–120 of 120
Villanova, J. A., Magalhães, M. A. B., de Souza, T. D. C., Battisti, M. K. B., Filho, J. R. E., Pimpão, C. T., Müeller, M. O., Arruda, P., & Capriglione, L. G. A. (2021) · Neuroscience Letters · doi:10.1016/j.neulet.2021.135973 · Cited by 1
Safety of Bevacizumab on Extraocular Muscle in a Rabbit Model
Jung, J. H., Lee, J. H., Lee, J. E., & Choi, H. Y. (2012) · Korean Journal of Ophthalmology · doi:10.3341/kjo.2012.26.4.290 · Cited by 1
“Recently, bevacizumab has been introduced as a new therapeutic strategy for many other ocular disorders, such as recurrent pterygium, neovascularization caused by chemical burns, viral infections of the cornea and bleb survival after glaucoma surgery [3-7].”
BackgroundConcentration change of TGF -β 1 in aqueous humor of rabbits
Yu, X., Wu, W., & Lu, X. (2014) · Asian Pacific Journal of Tropical Medicine · doi:10.1016/s1995-7645(14)60029-8 · Cited by 1
Intravitreal Bevacizumab as Adjunctive Therapy for Bleb Survival in Trabeculectomy in Rabbit Eyes
Echavez, M., Agulto, M. B., & Veloso, M. I. (2012) · Philippine Journal of Ophthalmology · Cited by 2
Pahor, D., & Gračner, T. (2019) · Spektrum der Augenheilkunde · doi:10.1007/s00717-019-0428-y · Cited by 1
Noh, S. M. M., Kadir, S. H. S. A., & Vasudevan, S. K. (2019) · Biomolecules · doi:10.3390/biom9060243 · Cited by 1
“Due to its potential as an antiangiogenic and antiproliferative agent, bevacizumab has been used “off record” in trabeculectomy as part of an antiscarring strategy [20,24,25].”
BackgroundHöh, H., Holland, U., & Medra, A. (2019) · Klinische Monatsblätter für Augenheilkunde · doi:10.1055/a-0972-1427 · Cited by 1
Wahyuni, I., Prastyani, R., Wiratama, A. B., Zuhria, I., & Widiyatno, T. V. (2024) · Pakistan Journal of Ophthalmology · doi:10.36351/pjo.v40i2.1760 · Cited by 1
Sengupta, S. (2013) · Journal of Glaucoma · doi:10.1097/ijg.0b013e3182877d1b · Cited by 1
Ferreira, J. D. L. M. (2015) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.17.2015.tde-03082015-143606
Lüke, J., Lüke, M., & Grisanti, S. (2016) · Essentials in ophthalmology/Essentials ophthalmology · doi:10.1007/978-3-319-24097-8_9
Sitoresmi, S. A. (2022) · Journal of Stem Cell Research and Tissue Engineering · doi:10.20473/jscrte.v6i2.42759
Arish, M., Sargazi, M., Dehghani, S., Sahami, M., Dashipour, A., Sarhadi, S., & Rouientan, H. (2023) · International Ophthalmology · doi:10.1007/s10792-023-02833-9
Preclinical validation of antifibrotic implantables for use in bleb-forming glaucoma surgery
van Mechelen, R. J. S. (2023) · Research Publications (Maastricht University) · doi:10.26481/dis.20231016rm
The Eye, Ear, and Ocular Adnexa
Lejeune, T., Gruebbel, M. M., & Lafond, J.-F. (2025) · Elsevier eBooks · doi:10.1016/b978-0-12-822528-8.00016-8
Tacrolimus Inhibits Human Tenon’s Fibroblast Migration, Proliferation, and Transdifferentiation
Hur, W., Park, J., Lee, J.-H., Chung, H.-S., Shin, J. A., Lee, H., Tchah, H., & Kim, J. Y. (2025) · Biomedicines · doi:10.3390/biomedicines13122956
Gomes, V. S. S. (2024) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Qian, T., Fu, M., Zhou, H., Zhang, Z., & Hu, Y. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1867803
Xing, P., Qu, W., Zhang, Y., Hu, X., Heman, X., Meng, B., Shao, H., & Wang, S. (2026) · Journal of Ophthalmology · doi:10.1155/joph/6946973
“…(rabbits) and patients with glaucoma, generally yielding favorable outcomes, and bevacizumab sub-conjunctival injections in an animal model of glaucoma fltration surgery resulted in blebs that were more durable, larger, elevated, and had reduced scarring when compared to the control group [37].”
Metadata
- Authors
- Memarzadeh, F., Varma, R., Lin, L.-T., Parikh, J. G., Dustin, L., Alcaraz, A., & Eliott, D.
- Affiliations
- Doheny Eye Institute (US)
- University of Southern California (US)
- Armed Forces Sung Shan General Hospital, Taipei, Taiwan, Republic of China; and
- Western University of Health Sciences (US)
- Venue
- Investigative Opthalmology & Visual Science
- Published
- 2009-07-01
- Volume
- 50
- Issue
- 7
- Pages
- 3233
- ISSN
- 0146-0404 (ISSN-L)
- 1552-5783
- OpenAlex
- W2154459059
- Cited by
- 117
- References
- 23
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 4 · 2023: 5 · 2022: 4 · 2021: 5 · 2020: 3 · 2019: 8 · 2018: 8 · 2017: 4 · 2016: 7 · 2015: 11 · 2014: 10 · 2013: 13 · 2012: 11
- FWCI
- 10.50
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Investigative Ophthalmology & Visual Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Ophthalmology › Glaucoma and retinal disorders
- Health Sciences › Medicine › Ophthalmology › Corneal surgery and disorders
- Health Sciences › Medicine › Ophthalmology › Intraocular Surgery and Lenses
- Keywords
- bevacizumab, trabeculectomy, glaucoma filtration surgery, bleb survival, postoperative scarring, antifibrotic therapy, 5-fluorouracil, subconjunctival injection, bleb fibrosis, rabbit model
- MeSH terms
- Bevacizumab, Animals, Antibodies, Monoclonal, Antimetabolites, Antineoplastic, Conjunctiva, Disease Models, Animal, Fibroblasts, Fibrosis, Fluorouracil, Glaucoma, Injections, Intraocular Pressure, Postoperative Care, Prognosis, Rabbits, Sclera, Trabeculectomy, Wound Healing, Angiogenesis Inhibitors, Vascular Endothelial Growth Factor A, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.